A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
Public ClinicalTrials.gov record NCT02215616. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to assess the efficacy of laquinimod as treatment in participants with HD after 52 weeks using the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS or TMS).
Study identification
- NCT ID
- NCT02215616
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 352 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 28, 2014 (Actual)
- Primary completion
- Jun 19, 2018 (Actual)
- Completion
- Jun 19, 2018 (Actual)
- Last update posted
- May 4, 2020
2014 – 2018
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 12566 | La Jolla | California | 92037 | — |
| Teva Investigational Site 12565 | Los Angeles | California | 90095 | — |
| Teva Investigational Site 12567 | San Francisco | California | 94143 | — |
| Teva Investigational Site 12575 | Englewood | Colorado | 80113 | — |
| Teva Investigational Site 13490 | Tampa | Florida | 33612 | — |
| Teva Investigational Site 13326 | Iowa City | Iowa | 52242 | — |
| Teva Investigational Site 12568 | Wichita | Kansas | 67226 | — |
| Teva Investigational Site 12574 | Baltimore | Maryland | 21287-0005 | — |
| Teva Investigational Site 12571 | Golden Valley | Minnesota | 55427 | — |
| Teva Investigational Site 12572 | St Louis | Missouri | 63110 | — |
| Teva Investigational Site 12570 | New York | New York | 10032 | — |
| Teva Investigational Site 12569 | Rochester | New York | 14618 | — |
| Teva Investigational Site 13489 | Memphis | Tennessee | 38163 | — |
| Teva Investigational Site 13325 | Nashville | Tennessee | 37232 | — |
| Teva Investigational Site 12815 | Houston | Texas | 77030 | — |
| Teva Investigational Site 12576 | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02215616, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2020 · Synced Nov 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02215616 live on ClinicalTrials.gov.